Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

Neuropsychopharmacology

Volumn 40, Issue , 2015, Pages 1084-1090

  Murrough, James W ^a   Burdick, Katherine E ^a   Levitch, Cara F ^a   Perez, Andrew M ^a   Brallier, Jess W ^a   Chang, Lee C ^b   Foulkes, Alexandra ^b   Charney, Dennis S ^a   Mathew, Sanjay J ^b,c   Iosifescu, Dan V ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MIDAZOLAM; ANTIDEPRESSANT AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM ASSESSMENT; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; WORKING MEMORY; AGED; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; COGNITION; DISEASE SEVERITY; FOLLOW UP; INTENTION TO TREAT ANALYSIS; MAJOR DEPRESSION; MINI MENTAL STATE EXAMINATION; PREDICTOR VARIABLE; PROBLEM SOLVING; SINGLE DRUG DOSE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; VISUAL MEMORY; WECHSLER MEMORY SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETAMINE; MALE; MIDAZOLAM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925487684     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.298     Document Type: Article

References (49)

1. Belujon P, Grace AA (2014). Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol Psychiatry (e-pub ahead of print).
2. Cabib S, Puglisi-Allegra S (2012). The mesoaccumbens dopamine in coping with stress. Neurosci Biobehav Rev 36: 79-89.
3. Cervenka S, Backman L, Cselenyi Z, Halldin C, Farde L (2008). Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. Neuroimage 40: 1287-1295.
4. Collie A, Maruff P, Darby DG, McStephen M (2003). The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 9: 419-428.
5. Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS et al (2013). Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. J Clin Psychiatry 74: 51-56.
6. Cropley VL, Fujita M, Innis RB, Nathan PJ (2006). Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59: 898-907.
7. Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ et al (2014). Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28: 536-544.
8. Edward Roberts R, Curran HV, Friston KJ, Morgan CJ (2014). Abnormalities in white matter microstructure associated with chronic ketamine use. Neuropsychopharmacology 39: 329-338.
9. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S et al (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71: 681-688.
10. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview for DSM-IV Axis Disorders (SCID). New York State Psychiatric Institute, Biometrics Research: New York, NY, USA.
11. Folstein MF, Folstein SE, McHugh PR (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
12. Green SM, Cote CJ (2009). Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med 54: 181-190.
13. Kapur S, Phillips AG, Insel TR (2012). Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 17: 1174-1179.
14. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL et al (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48: 627-640.
15. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al (1999). Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145: 193-204.
16. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
17. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A et al (2005). Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62: 985-994.
18. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N et al (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72: e27-e28.
19. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
20. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H et al (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754-761.
21. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 71: 996-1005.
22. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010). Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13: 71-82.
23. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
24. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
25. Morgan CJ, Curran HV (2006). Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl) 188: 408-424.
26. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29: 208-218.
27. Morgan CJ, Muetzelfeldt L, Curran HV (2009). Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104: 77-87.
28. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170: 1134-1142.
29. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M et al (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250-256.
30. Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B et al (2014). Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 231: 481.
31. Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM et al (2014). Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 75: e417-e423.
32. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD et al (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203-213.
33. Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N et al (2014). Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16: 119-128.
34. Parwani A, Weiler MA, Blaxton TA, Warfel D, Hardin M, Frey K et al (2005). The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) 183: 265-274.
35. Perlis RH (2013). A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry 74: 7-14.
36. Perry EB Jr, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A et al Yale Ketamine Study Group (2007). Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 192: 253-260.
37. Rabiner EA (2007). Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?J Psychopharmacol 21: 253-258.
38. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996). The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 26: 477-486.
39. Sackeim HA (2001). The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16): 10-17.
40. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA Jr et al (2009). Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65: 289-295.
41. Semkovska M, McLoughlin DM (2010). Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry 68: 568-577.
42. Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO (2014). Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17: 1805-1813.
43. Simon GE, Perlis RH (2010). Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167: 1445-1455.
44. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA et al (1998). Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18: 18-25.
45. Trivedi MH (2013). Modeling predictors, moderators and mediators of treatment outcome and resistance in depression. Biol Psychiatry 74: 2-4.
46. Uddin M (2014). Blood-based biomarkers in depression: emerging themes in clinical research. Mol Diagn Ther 18: 469-482.
47. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71: 939-946.
48. Zarate CA Jr, Mathews DC, Furey ML (2013). Human biomarkers of rapid antidepressant effects. Biol Psychiatry 73: 1142-1155.
49. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.